Jane Meisel

3.7k total citations · 1 hit paper
85 papers, 1.7k citations indexed

About

Jane Meisel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jane Meisel has authored 85 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 27 papers in Cancer Research. Recurrent topics in Jane Meisel's work include HER2/EGFR in Cancer Research (29 papers), Advanced Breast Cancer Therapies (22 papers) and Breast Cancer Treatment Studies (19 papers). Jane Meisel is often cited by papers focused on HER2/EGFR in Cancer Research (29 papers), Advanced Breast Cancer Therapies (22 papers) and Breast Cancer Treatment Studies (19 papers). Jane Meisel collaborates with scholars based in United States, Spain and Italy. Jane Meisel's co-authors include C.E. Rubin, David Perera, Xiaoxian Li, Limin Peng, Ruth O’Regan, Jing Yang, Mylin A. Torres, Lei Huo, Kevin C. Ward and Ayşegül A. Şahin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Jane Meisel

78 papers receiving 1.6k citations

Hit Papers

Overwhelming Watery Diarr... 1976 2026 1992 2009 1976 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Overwhelming Watery Diarrhea Associated with a Cryptosporidium in an Immunosuppressed Patient
    1976 323 citations Jane Meisel et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jane Meisel 729 412 288 281 255 85 1.7k
Richard N. Miller 422 0.6× 114 0.3× 242 0.8× 185 0.7× 331 1.3× 51 1.7k
K Friese 419 0.6× 209 0.5× 45 0.2× 173 0.6× 456 1.8× 230 2.4k
T. Klingebiel 467 0.6× 218 0.5× 57 0.2× 130 0.5× 428 1.7× 62 1.9k
Agostino Riva 661 0.9× 174 0.4× 69 0.2× 122 0.4× 534 2.1× 122 3.0k
François Lefrère 822 1.1× 49 0.1× 59 0.2× 211 0.8× 187 0.7× 79 2.9k
Gérard Michel 314 0.4× 77 0.2× 81 0.3× 117 0.4× 234 0.9× 77 1.8k
Yao Tettey 248 0.3× 114 0.3× 55 0.2× 177 0.6× 174 0.7× 55 1.3k
Jing‐Houng Wang 427 0.6× 383 0.9× 58 0.2× 235 0.8× 322 1.3× 215 4.9k
Aaron S. Rosenberg 438 0.6× 64 0.2× 45 0.2× 116 0.4× 468 1.8× 87 1.9k

Countries citing papers authored by Jane Meisel

Since Specialization
Citations

This map shows the geographic impact of Jane Meisel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Meisel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Meisel more than expected).

Fields of papers citing papers by Jane Meisel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Meisel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Meisel. The network helps show where Jane Meisel may publish in the future.

Co-authorship network of co-authors of Jane Meisel

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Meisel. A scholar is included among the top collaborators of Jane Meisel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Meisel. Jane Meisel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lawal, Ismaheel O., Xiaoxian Li, Clara R. Farley, et al.. (2025). Negative 18F-FES PET/CT Despite Estrogen Receptor Positivity by Immunohistochemistry. Clinical Nuclear Medicine. 51(4). e244–e246.
2.
3.
Moore, George E., et al.. (2024). Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment. SHILAP Revista de lepidopterología. 16. 100337–100337. 1 indexed citations
4.
Jeselsohn, Rinath, Jingxin Fu, Reshma Mahtani, et al.. (2024). Abstract PS12-02: Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2- Metastatic Breast Cancer. Cancer Research. 84(9_Supplement). PS12–2. 1 indexed citations
5.
Meisel, Jane, Katia Khoury, A. Jo Chien, et al.. (2024). Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA509–LBA509. 4 indexed citations
6.
Wood, S.J., Ji‐Hoon Lee, Jessica Chen, et al.. (2024). High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy. Breast Cancer Research and Treatment. 205(1). 193–199. 18 indexed citations
7.
Graetz, Ilana, Samuel Hernández, Jane Meisel, et al.. (2024). Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial. JCO Oncology Practice. 20(10). 1376–1383.
8.
Goldfarb, Shari, Sarah Sammons, Jane Meisel, et al.. (2024). Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study. Clinical Breast Cancer. 25(3). 261–267.e1. 1 indexed citations
9.
Adeyelu, Tolulope, Andrew Elliott, Phillip L. Walker, et al.. (2024). Genomic and transcriptomic landscape of HER2-low breast cancer. Breast Cancer Research and Treatment. 209(2). 323–330. 4 indexed citations
10.
Taylor, Caitlin, Jane Meisel, Aimee J. Foreman, et al.. (2023). Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. Breast Cancer Research and Treatment. 199(1). 91–98. 5 indexed citations
11.
Goldfarb, Shari, Sarah Sammons, Jane Meisel, et al.. (2023). (114) Vaginal/Vulvar Symptoms with Lasofoxifene versus Fulvestrant in ESR1-mutated, ER+/HER2- Metastatic Breast Cancer Patients. The Journal of Sexual Medicine. 20(Supplement_2). 2 indexed citations
12.
Bustos, Matías A., Estelamari Rodríguez, Sarah Sammons, et al.. (2023). Abstract HER2-12: HER2-12 Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer. Cancer Research. 83(5_Supplement). HER2–12. 2 indexed citations
13.
14.
Sadigh, Gelareh, et al.. (2023). Improving palbociclib adherence among women with metastatic breast cancer using a CONnected CUstomized Treatment Platform: A pilot study. Journal of Oncology Pharmacy Practice. 29(8). 1957–1964. 2 indexed citations
15.
Meisel, Jane, et al.. (2022). When the personal becomes political: The impact of the Dobbs decision on women with cancer. Cancer. 129(2). 171–174. 1 indexed citations
16.
Zhao, Jing, Uma Krishnamurti, Chao Zhang, et al.. (2020). HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology - Research and Practice. 216(11). 153155–153155. 14 indexed citations
17.
18.
Meisel, Jane, Jing Zhao, Aili Suo, et al.. (2019). Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer. Clinical Breast Cancer. 20(1). 19–24. 30 indexed citations
19.
Meisel, Jane, Vyshak Alva Venur, Michael Gnant, & Lisa A. Carey. (2018). Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. American Society of Clinical Oncology Educational Book. 38(38). 78–86. 44 indexed citations
20.
Meisel, Jane, Chao Zhang, Pia R. Mendoza, et al.. (2017). Evaluation of Prognosis in Hormone Receptor–Positive/HER2-Negative and Lymph Node–Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clinical Breast Cancer. 18(5). 347–352. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard N. Miller Breakdown of academic impact, for papers by K Friese Breakdown of academic impact, for papers by T. Klingebiel Breakdown of academic impact, for papers by Agostino Riva Breakdown of academic impact, for papers by François Lefrère Breakdown of academic impact, for papers by Gérard Michel Breakdown of academic impact, for papers by Yao Tettey Breakdown of academic impact, for papers by Jing‐Houng Wang Breakdown of academic impact, for papers by Aaron S. Rosenberg
Rankless by CCL
2026